Safety and low molecular weight heparin in older people in a hospital with ambulatory care

Archives of Gerontology and Geriatrics

Volumn 43, Issue 2, 2006, Pages 233-241

  Chan, Daniel K Y ^a   Ong, Bin ^b   Almafragy, Hamid ^a   Karr, Margaret ^a   Hung, Arthur W T ^c   Liu, Jun G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c BreastScreen NSW   (Australia)

Author keywords

Age 70; Ambulatory care; Bleeding; Low molecular weight heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; RALOXIFENE; STEROID; TAMOXIFEN; WARFARIN;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULATION; ARTICLE; BLEEDING; COMORBIDITY; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG SAFETY; FEMALE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; AMBULATORY CARE; ANTICOAGULANTS; BLOOD COAGULATION; DRUG TOXICITY; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MEDICAL RECORDS; MIDDLE AGED; NEW SOUTH WALES; PARTIAL THROMBOPLASTIN TIME; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 33747255746     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2005.10.011     Document Type: Article

References (17)

1. Beyth R.J., and Landefeld C.S. Anticoagulants in older patients, a safety perspective. Drugs Aging 6 (1995) 45-54
2. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
3. De Valk H.W., Banga J.D., Wester J.W., Brouwer C.B., Van Hessen M.W., Meuwissen O.J., Hart H.C., Sixma J.J., and Nieuwenhuis H.K. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann. Int. Med. 123 (1995) 1-9
4. Gitter M.J., Jaeger T.M., Petterson T.M., Gersh B., and Silverstein M.D. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin. Proc. 70 (1995) 725-733
5. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G., Lerner R.G., Hall J., Sparling T., and Brettell H.R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326 (1992) 975-982
6. Koopman M.M.V., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M., Van der Meer J., Gallus A.S., Simonneau G., Chesterman C.H., Prins M.H., Bossuyt P.M.M., De Haes H., Van den Belt A.G.M., Sagnard L., d'Azemar P., and Büller H.R. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334 (1996) 682-687
7. Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95 (1993) 315-328
8. Landefeld C.S., and Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87 (1989) 144-152
9. Landefeld C.S., Cook E.F., Flatley M., Weisberg M., and Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am. J. Med. 82 (1987) 703-713
10. Landefeld C.S., McGuire III E., and Rosenblatt M.W. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am. J. Med. 89 (1990) 569-578
11. Rocha E., Martinez-Gonzalez M.A., Montes R., and Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 85 (2000) 935-942
12. Simonneau G., Sors H., Charbonnier B., Page Y., Laaban J.P., Azarian R., Laurent M., Hirsch J.L., Ferrari E., Bosson J.L., Mottier D., and Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. 337 (1997) 663-669
13. Van Dongen C.J.J., Van den Belt A.G.M., Prins M.H., and Lensing A.W.A. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews (2004), John Wiley & Sons Ltd, Chichester, UK. http://www.cochrane.org/reviews/en/ab001100.html 10.1002/14651858.CD001100.pub2
14. Walker A.M., and Jick H. Predictors of bleeding during heparin therapy. J. Am. Med. Assoc. 244 (1980) 1209-1212
15. Weitz J.I. Drug therapy: low-molecular-weight heparins. N. Engl. J. Med. 337 (1997) 688-698
16. Wells P.S. Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Curr. Opin. Pulm. Med. 7 (2001) 360-364
17. Wester J.P., De Valk H.W., Nieuwenhuis H.K., Brouwer C.B., Van der Graaf Y., Meuwissen O.J., Hart H.C., Sixma J.J., and Banga J.D. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb. Haemost. 76 (1996) 682-688